Quick Answer
Vistagen Therapeutics, Inc. reported Research And Development Expense of $39.38 million for the year ending 2025.
- Vistagen Therapeutics, Inc. showed an increase of +96.7% in Research And Development Expense from 2024 to 2025.
- This data is from Vistagen Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on June 17, 2025.
- XBRL data for this metric is available from 2011 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2010: $674.8 thousand | Q3 2010: $691.9 thousand | Q4 2010: $446.8 thousand | Q2 2011: $1.03 million | Q3 2011: $1.23 million | Q4 2011: $1.31 million | Q1 2012: $1.83 million | Q2 2012: $866.3 thousand | Q3 2012: $1.11 million | Q4 2012: $1.12 million | Q1 2013: $339.0 thousand | Q2 2013: $695.5 thousand | Q2 2014: $474.0 thousand | Q3 2014: $558.0 thousand | Q4 2014: $445.0 thousand | Q1 2015: $956.0 thousand | Q2 2015: $373.0 thousand | Q3 2015: $1.66 million | Q4 2015: $806.0 thousand | Q1 2016: $1.10 million | Q2 2016: $826.0 thousand | Q3 2016: $1.61 million | Q4 2016: $1.61 million | Q1 2017: $1.16 million | Q2 2017: $1.10 million | Q3 2017: $2.43 million | Q4 2017: $1.60 million | Q1 2018: $2.64 million | Q2 2018: $2.74 million | Q3 2018: $5.26 million | Q4 2018: $5.34 million | Q1 2019: $3.76 million | Q2 2019: $4.31 million | Q3 2019: $4.21 million | Q4 2019: $3.02 million | Q1 2020: $1.84 million | Q2 2020: $1.73 million | Q3 2020: $2.36 million | Q4 2020: $3.50 million | Q1 2021: $4.89 million | Q2 2021: $5.46 million | Q3 2021: $9.94 million | Q4 2021: $7.78 million | Q1 2022: $12.23 million | Q2 2022: $15.29 million | Q3 2022: $12.89 million | Q4 2022: $6.85 million | Q1 2023: $9.34 million | Q2 2023: $4.20 million | Q3 2023: $3.85 million | Q4 2023: $4.54 million | Q2 2024: $7.65 million | Q3 2024: $10.22 million | Q4 2024: $11.31 million | Q2 2025: $11.68 million | Q3 2025: $15.92 million | Q4 2025: $14.22 million.
- Over the full 14 years of available data (2011 to 2025), Vistagen Therapeutics, Inc.'s Research And Development Expense has grown by 970.5%.
- Historical annual values: Fiscal year 2025: $39.38 million | Fiscal year 2024: $20.02 million | Fiscal year 2023: $44.38 million | Fiscal year 2022: $35.41 million | Fiscal year 2021: $11.93 million | Fiscal year 2020: $13.37 million | Fiscal year 2019: $17.10 million | Fiscal year 2018: $7.76 million | Fiscal year 2017: $5.20 million | Fiscal year 2016: $3.93 million | Fiscal year 2015: $2.43 million | Fiscal year 2013: $3.43 million | Fiscal year 2012: $5.39 million | Fiscal year 2011: $3.68 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: